Guided Therapeutics (GTHP) Long-Term Debt Repayments (2018 - 2025)
Guided Therapeutics recorded quarterly Long-Term Debt Repayments of $187000.0 in Q4 2025, up 98.94% quarter-over-quarter from $94000.0 in Q3 2025, and down 6.03% year-over-year from $199000.0 in Q4 2024.
Guided Therapeutics' Long-Term Debt Repayments history runs 8 years deep, the most recent figure standing at $187000.0 for Q4 2025.
- In Q4 2025, Long-Term Debt Repayments fell 6.03% year-over-year to $187000.0; the TTM figure through Dec 2025 stood at $499000.0 (up 13.93% YoY), while the FY2025 annual figure was $499000.0, up 13.93% from the prior year.
- Long-Term Debt Repayments came in at $187000.0 for Q4 2025 at Guided Therapeutics, up from $94000.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $811000.0 in Q2 2021 to a low of $41000.0 in Q2 2023.
- A 5-year average of $180944.4 and a median of $116500.0 in 2024 frame the typical range for Long-Term Debt Repayments.
- Across the five-year window, Long-Term Debt Repayments tumbled 94.7% in 2022 and soared 342.22% in 2024, its largest moves.
- Guided Therapeutics' Long-Term Debt Repayments stood at $811000.0 in 2021, then tumbled by 90.75% to $75000.0 in 2022, then plunged by 40.0% to $45000.0 in 2023, then jumped by 342.22% to $199000.0 in 2024, then declined by 6.03% to $187000.0 in 2025.
- According to Business Quant data, Long-Term Debt Repayments over the past three periods registered $187000.0, $94000.0, and $71000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.42 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 1.00 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Guided Therapeutics | - | - | 458,000.00 | 187,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 187,000.00 |
| Dec 31, 2025 | 187,000.00 |
| Sep 30, 2025 | 94,000.00 |
| Sep 30, 2025 | 94,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Dec 31, 2024 | 199,000.00 |
| Dec 31, 2024 | 199,000.00 |
| Sep 30, 2024 | 54,000.00 |
| Sep 30, 2024 | 54,000.00 |
| Jun 30, 2024 | 139,000.00 |
| Jun 30, 2024 | 139,000.00 |
| Mar 31, 2024 | 46,000.00 |
| Mar 31, 2024 | 46,000.00 |
| Dec 31, 2023 | 45,000.00 |
| Dec 31, 2023 | 45,000.00 |
| Sep 30, 2023 | 154,000.00 |
| Sep 30, 2023 | 154,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 41,000.00 |
| Mar 31, 2023 | 172,000.00 |
| Mar 31, 2023 | 172,000.00 |
| Dec 31, 2022 | 75,000.00 |
| Dec 31, 2022 | 75,000.00 |
| Sep 30, 2022 | 332,000.00 |
| Sep 30, 2022 | 332,000.00 |
| Jun 30, 2022 | 43,000.00 |
| Jun 30, 2022 | 43,000.00 |
| Mar 31, 2022 | 90,000.00 |
| Mar 31, 2022 | 90,000.00 |
| Jun 30, 2021 | 811,000.00 |
| Jun 30, 2021 | 811,000.00 |
| Mar 31, 2021 | 557,000.00 |
| Mar 31, 2021 | 557,000.00 |
| Dec 31, 2020 | 142,000.00 |
| Dec 31, 2020 | 142,000.00 |
| Sep 30, 2020 | 262,000.00 |
| Sep 30, 2020 | 262,000.00 |
| Jun 30, 2020 | 246,000.00 |
| Jun 30, 2020 | 246,000.00 |
| Mar 31, 2020 | 451,000.00 |
| Mar 31, 2020 | 451,000.00 |
| Dec 31, 2019 | 135,000.00 |
| Dec 31, 2019 | 135,000.00 |
| Sep 30, 2019 | 46,000.00 |
| Sep 30, 2019 | 46,000.00 |
| Jun 30, 2019 | 62,000.00 |
| Jun 30, 2019 | 62,000.00 |
| Mar 31, 2019 | 38,000.00 |
| Mar 31, 2019 | 38,000.00 |
| Sep 30, 2018 | 40,000.00 |
| Sep 30, 2018 | 40,000.00 |
| Jun 30, 2018 | 114,000.00 |
| Jun 30, 2018 | 114,000.00 |